A therapeutic role for cyclooxygenase-2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis.

The FASEB journal : official publication of the Federation of American Societies for Experimental Biology

Volumn 17, Issue 6, 2003, Pages 725-727

  Pompl, P N ^a   Ho, L ^a   Bianchi, M ^a   McManus, T ^a   Qin, W ^a   Pasinetti, G M ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; ISOENZYME; NIMESULIDE; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; SULFONAMIDE; SUPEROXIDE DISMUTASE;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL; ARTICLE; BLOOD; DISEASE MODEL; DRUG EFFECT; GENETICS; METABOLISM; MOTOR ACTIVITY; MOUSE; MUTATION; PATHOPHYSIOLOGY; SPINAL CORD; TRANSGENIC MOUSE;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DINOPROSTONE; DISEASE MODELS, ANIMAL; ISOENZYMES; MICE; MICE, TRANSGENIC; MOTOR ACTIVITY; MUTATION; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; SPINAL CORD; SULFONAMIDES; SUPEROXIDE DISMUTASE;

EID: 0037389393     PISSN: None     EISSN: 15306860     Source Type: Journal    
DOI: 10.1096/fj.02-0876fje     Document Type: Article

References (0)